Why Oxford-AstraZeneca Pausing COVID Vaccine Trial is a Good Sign

Are these snags in vaccine trials normal or does this call for a re-assessment of this vaccine race?

Published
Podcast
1 min read

The COVID vaccine race has faced a hurdle, after a participant in the Oxford-AstraZeneca trials developed neurological symptoms, prompting the company to pause the trials voluntarily.

Health care news publication Stat reported that the participant was a woman and she did receive the vaccine as opposed to a placebo and that her symptoms were similar to a rare but serious spinal inflammatory disorder called transverse myelitis.

Now the AstraZeneca-Oxford research has been the frontrunner in the global race for a COVID-19 vaccine as we know, and this hurdle has triggered a global shutdown of the phase 2 and phase 3 trials.

As questions are rife on social media over this development, are these snags normal or does this call for a re-assessment of this vaccine race? And secondly, what’s the road ahead on the trial timeline? Tune in to The Big Story!

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!